1. Kaushik Sampathkumar Project Manager, Business Development Inogent Laboratories (GVK BIO company) India
2.
3.
4.
5.
6. Source: Datamonitor. Pharmaceutical Company Outlook to 2014. Dec 2009. The 2002-08 CAGR was 10.5%...highlighting the challenges pharma is facing today…… Prescription sales growth rate is stalled at about 1.2% - largely due to the much discussed ‘patent cliff’
7.
8. Patent cliff is nearly 6x that in 2002-2008 Pfizer’s Lipitor comes off patent in 2011 and had $12.4b in 2008 sales Core sales also highly impacted by indirect generic competition Source: Datamonitor. Pharmaceutical Company Outlook to 2014. Dec 2009.